Shire pLc announces that the UK as reference state has validated the MAA for lifitegrast as a treatment for dry eye disease.

Shire plc announces that the Marketing Authorization Application (MAA) for lifitegrast, submitted on 7 August 2017, has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP). If approved, lifitegrast would be the first and only treatment in a new class of drugs (LFA-1 antagonist) to address the signs and symptoms of dry eye disease in adults in Europe.

The disease is most commonly associated with eye dryness and overall eye discomfort, as well as stinging, burning, and fluctuating blurry vision. Dry eye disease may significantly affect quality of life and may impact activities such as reading and using computer. It is one of the most common conditions seen by ophthalmologists and eye care practitioners worldwide.